Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression

Marlene P. Freeman, George I. Papakostas, Bettina Hoeppner, Erica Mazzone, Heidi Judge, Cristina Cusin, Sanjay Mathew, Gerard Sanacora, Dan Iosifescu, Charles DeBattista, Madhukar H Trivedi, Maurizio Fava

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: While ketamine has been increasingly studied for treatment resistant depression (TRD), the impact of sex differences on treatment outcomes has not been well studied. The objective was to ascertain whether there were differences in response to a single administration of ketamine for TRD between men and women, and between pre- and post-menopausal women. Methods: A randomized, double-blind, placebo-controlled trial (N = 99; N = 50 male; N = 49 female) was conducted to investigate the efficacy of intravenous ketamine versus active placebo as augmentation of antidepressant therapy for TRD. Patients were assigned to one of five arms; one-time administration of ketamine of varying doses (i.e., 0.1, 0.2, 0.5, and 1.0 mg/kg), and one group receiving active placebo (intravenous midazolam). A priori-planned analyses were conducted to compare responses between women and men, as well pre-vs. postmenopausal women. Results: Analyses demonstrated no significant differences between women and men in terms of treatment response (F(1,80) = 0.06, p = 0.80). There were no significant differences in the frequency of adverse effects (AEs) reported by those assigned to ketamine treatment groups (p > 0.21 for all AEs reported more than once), although women reported more headaches (12% vs. 6%, p = 0.30) and nausea (10% vs. 6%, p = 0.47). In comparing pre-vs. postmenopausal women, no differences in efficacy were observed (F(1,76) = 0.36, p = 0.55). Conclusions: Results do not support differential efficacy or tolerability of ketamine for the treatment of TRD between women and men, nor based on menopause status among women. However, larger trials with these a priori aims are needed to confirm these results.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
JournalJournal of Psychiatric Research
Volume110
DOIs
StatePublished - Mar 1 2019

Fingerprint

Treatment-Resistant Depressive Disorder
Ketamine
Sex Characteristics
Placebos
Women's Rights
Midazolam
Menopause
Nausea
Antidepressive Agents
Headache
Therapeutics

Keywords

  • Depression
  • Ketamine
  • Menopause
  • Sex differences
  • Treatment resistant

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. / Freeman, Marlene P.; Papakostas, George I.; Hoeppner, Bettina; Mazzone, Erica; Judge, Heidi; Cusin, Cristina; Mathew, Sanjay; Sanacora, Gerard; Iosifescu, Dan; DeBattista, Charles; Trivedi, Madhukar H; Fava, Maurizio.

In: Journal of Psychiatric Research, Vol. 110, 01.03.2019, p. 166-171.

Research output: Contribution to journalArticle

Freeman, MP, Papakostas, GI, Hoeppner, B, Mazzone, E, Judge, H, Cusin, C, Mathew, S, Sanacora, G, Iosifescu, D, DeBattista, C, Trivedi, MH & Fava, M 2019, 'Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression', Journal of Psychiatric Research, vol. 110, pp. 166-171. https://doi.org/10.1016/j.jpsychires.2019.01.010
Freeman, Marlene P. ; Papakostas, George I. ; Hoeppner, Bettina ; Mazzone, Erica ; Judge, Heidi ; Cusin, Cristina ; Mathew, Sanjay ; Sanacora, Gerard ; Iosifescu, Dan ; DeBattista, Charles ; Trivedi, Madhukar H ; Fava, Maurizio. / Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. In: Journal of Psychiatric Research. 2019 ; Vol. 110. pp. 166-171.
@article{c2296c8423a948ab9c0fd569cfced8d4,
title = "Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression",
abstract = "Background: While ketamine has been increasingly studied for treatment resistant depression (TRD), the impact of sex differences on treatment outcomes has not been well studied. The objective was to ascertain whether there were differences in response to a single administration of ketamine for TRD between men and women, and between pre- and post-menopausal women. Methods: A randomized, double-blind, placebo-controlled trial (N = 99; N = 50 male; N = 49 female) was conducted to investigate the efficacy of intravenous ketamine versus active placebo as augmentation of antidepressant therapy for TRD. Patients were assigned to one of five arms; one-time administration of ketamine of varying doses (i.e., 0.1, 0.2, 0.5, and 1.0 mg/kg), and one group receiving active placebo (intravenous midazolam). A priori-planned analyses were conducted to compare responses between women and men, as well pre-vs. postmenopausal women. Results: Analyses demonstrated no significant differences between women and men in terms of treatment response (F(1,80) = 0.06, p = 0.80). There were no significant differences in the frequency of adverse effects (AEs) reported by those assigned to ketamine treatment groups (p > 0.21 for all AEs reported more than once), although women reported more headaches (12{\%} vs. 6{\%}, p = 0.30) and nausea (10{\%} vs. 6{\%}, p = 0.47). In comparing pre-vs. postmenopausal women, no differences in efficacy were observed (F(1,76) = 0.36, p = 0.55). Conclusions: Results do not support differential efficacy or tolerability of ketamine for the treatment of TRD between women and men, nor based on menopause status among women. However, larger trials with these a priori aims are needed to confirm these results.",
keywords = "Depression, Ketamine, Menopause, Sex differences, Treatment resistant",
author = "Freeman, {Marlene P.} and Papakostas, {George I.} and Bettina Hoeppner and Erica Mazzone and Heidi Judge and Cristina Cusin and Sanjay Mathew and Gerard Sanacora and Dan Iosifescu and Charles DeBattista and Trivedi, {Madhukar H} and Maurizio Fava",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.jpsychires.2019.01.010",
language = "English (US)",
volume = "110",
pages = "166--171",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression

AU - Freeman, Marlene P.

AU - Papakostas, George I.

AU - Hoeppner, Bettina

AU - Mazzone, Erica

AU - Judge, Heidi

AU - Cusin, Cristina

AU - Mathew, Sanjay

AU - Sanacora, Gerard

AU - Iosifescu, Dan

AU - DeBattista, Charles

AU - Trivedi, Madhukar H

AU - Fava, Maurizio

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: While ketamine has been increasingly studied for treatment resistant depression (TRD), the impact of sex differences on treatment outcomes has not been well studied. The objective was to ascertain whether there were differences in response to a single administration of ketamine for TRD between men and women, and between pre- and post-menopausal women. Methods: A randomized, double-blind, placebo-controlled trial (N = 99; N = 50 male; N = 49 female) was conducted to investigate the efficacy of intravenous ketamine versus active placebo as augmentation of antidepressant therapy for TRD. Patients were assigned to one of five arms; one-time administration of ketamine of varying doses (i.e., 0.1, 0.2, 0.5, and 1.0 mg/kg), and one group receiving active placebo (intravenous midazolam). A priori-planned analyses were conducted to compare responses between women and men, as well pre-vs. postmenopausal women. Results: Analyses demonstrated no significant differences between women and men in terms of treatment response (F(1,80) = 0.06, p = 0.80). There were no significant differences in the frequency of adverse effects (AEs) reported by those assigned to ketamine treatment groups (p > 0.21 for all AEs reported more than once), although women reported more headaches (12% vs. 6%, p = 0.30) and nausea (10% vs. 6%, p = 0.47). In comparing pre-vs. postmenopausal women, no differences in efficacy were observed (F(1,76) = 0.36, p = 0.55). Conclusions: Results do not support differential efficacy or tolerability of ketamine for the treatment of TRD between women and men, nor based on menopause status among women. However, larger trials with these a priori aims are needed to confirm these results.

AB - Background: While ketamine has been increasingly studied for treatment resistant depression (TRD), the impact of sex differences on treatment outcomes has not been well studied. The objective was to ascertain whether there were differences in response to a single administration of ketamine for TRD between men and women, and between pre- and post-menopausal women. Methods: A randomized, double-blind, placebo-controlled trial (N = 99; N = 50 male; N = 49 female) was conducted to investigate the efficacy of intravenous ketamine versus active placebo as augmentation of antidepressant therapy for TRD. Patients were assigned to one of five arms; one-time administration of ketamine of varying doses (i.e., 0.1, 0.2, 0.5, and 1.0 mg/kg), and one group receiving active placebo (intravenous midazolam). A priori-planned analyses were conducted to compare responses between women and men, as well pre-vs. postmenopausal women. Results: Analyses demonstrated no significant differences between women and men in terms of treatment response (F(1,80) = 0.06, p = 0.80). There were no significant differences in the frequency of adverse effects (AEs) reported by those assigned to ketamine treatment groups (p > 0.21 for all AEs reported more than once), although women reported more headaches (12% vs. 6%, p = 0.30) and nausea (10% vs. 6%, p = 0.47). In comparing pre-vs. postmenopausal women, no differences in efficacy were observed (F(1,76) = 0.36, p = 0.55). Conclusions: Results do not support differential efficacy or tolerability of ketamine for the treatment of TRD between women and men, nor based on menopause status among women. However, larger trials with these a priori aims are needed to confirm these results.

KW - Depression

KW - Ketamine

KW - Menopause

KW - Sex differences

KW - Treatment resistant

UR - http://www.scopus.com/inward/record.url?scp=85060346474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060346474&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2019.01.010

DO - 10.1016/j.jpsychires.2019.01.010

M3 - Article

C2 - 30641350

AN - SCOPUS:85060346474

VL - 110

SP - 166

EP - 171

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -